Phani Veeranki
Overview
Explore the profile of Phani Veeranki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
24
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wu S, Vu M, Motawakel O, Bancroft T, Johnson K, Song R, et al.
J Med Econ
. 2025 Mar;
28(1):413-424.
PMID: 40062655
Aims: Systemic corticosteroids (SCS) are used to manage asthma exacerbations. Among the broad population of patients with asthma, SCS-related risk of adverse events (AEs), health care resource utilization (HCRU), and...
2.
Yang J, Steffens A, Olson A, Anderson A, Basra G, Veeranki P, et al.
Respir Res
. 2025 Feb;
26(1):80.
PMID: 40022082
Background: Supplemental oxygen therapy is commonly prescribed in clinical practice for patients with fibrosing interstitial lung disease (ILD) to reduce breathlessness and increase physical capacity. Only a few studies have...
3.
Han J, Silver J, Dhangar I, Veeranki P, Deb A
Ann Allergy Asthma Immunol
. 2024 Oct;
PMID: 39428097
Background: Real-world burden data on systemic corticosteroid (SCS) use in chronic rhinosinusitis with nasal polyps (CRSwNP) are limited. Objective: To describe the real-world burden of SCS in CRSwNP. Methods: This...
4.
McCormack M, Paczkowski R, Gronroos N, Noorduyn S, Lee L, Veeranki P, et al.
Adv Ther
. 2024 Feb;
41(3):1245-1261.
PMID: 38310193
Introduction: Triple therapy (fluticasone furoate/umeclidinium/vilanterol; FF/UMEC/VI) has been shown to improve symptoms and reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) and a history of exacerbations. This real-world...
5.
Nili M, Steffens A, Anderson A, Brekke L, Grace Johnson M, Veeranki P, et al.
J Manag Care Spec Pharm
. 2024 Feb;
30(2):163-174.
PMID: 38308627
Background: Fibrosing interstitial lung disease (ILD) encompasses more than 200 diverse pulmonary disorders, of which up to 40% become progressive. The 4 underlying ILD types most likely to result in...
6.
Grivas P, Veeranki P, Chiu K, Pawar V, Chang J, Bharmal M
Future Oncol
. 2023 Mar;
19(5):369-383.
PMID: 36876486
Investigate oncologist and patient preferences for the first-line treatment of advanced urothelial carcinoma. A discrete-choice experiment was used to elicit treatment attribute preferences, including patient treatment experience (number and duration...
7.
Ogdie A, Hwang M, Pedro S, Veeranki P, Yi E, Hass S, et al.
Rheumatology (Oxford)
. 2022 Dec;
62(6):e182-e184.
PMID: 36469081
No abstract available.
8.
Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, et al.
J Manag Care Spec Pharm
. 2022 Aug;
28(9):1008-1020.
PMID: 36001102
Interventions for ankylosing spondylitis (AS) have improved patient-reported outcomes (PROs) in clinical studies. However, limited data exist associating these improvements with health care resource utilization (HCRU) or cost savings. Few...
9.
Ogdie A, Hwang M, Veeranki P, Portelli A, Sison S, Shafrin J, et al.
J Manag Care Spec Pharm
. 2022 Aug;
28(9):997-1007.
PMID: 36001101
The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient functional status. Significant improvements in the...
10.
Fergie J, Pawaskar M, Veeranki P, Samant S, Harley C, MacEwan J, et al.
PLoS One
. 2022 Jun;
17(6):e0269596.
PMID: 35749342
Background: In 1995, the CDC recommended one-dose routine varicella immunization for children <12 years of age, expanding its recommendation to two doses in 2006. Today, with widespread varicella vaccination coverage,...